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lnterleukin-6 (IL-6) induces changes in gene expression and the N-glycosylation pattern of acute-phase proteins in hepatoeylcs. IL-6 exerts its action 
via a cell surface receptor complex consisting of an 80 kDa IL-6 biuding protein (gpg0) and a 130 kDa glycoprotein (gpl30) involved in signal 
transduction. A genetically engineered 8pS0-derlved soluble human IL-6.receptor (shlL-6-R) significantly enhanced the IL-6 effect on N-glyco~yl- 
ation changes (revealed by reactivity with the lectin-concanavalin A) of a~-protease inhibitor (Pl) secreted by human hepatoma cells eHepO2). Stable 
transfection of IL-6-cDNA into HepG2 ceils (HepG2-1L-6) resulting in constitutive secretion of 2/~g of IL-6 per 106 cells in 24 h led to a 
down.regulation f surface-bound gpg0 and subsequent homologous desensitization f HepG2-1L-6 cells towards IL-6. Soluble human IL-6-R 
functionally substituted membrane-bound gpg0 resulting in a reconstitution f responsiveness of HepG2-1L-6 cells. 
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1. INTRODUCTION 
IL-6 is a major hepatocyte stimulating factor [1,2]. It 
regulates the expression of a number of plasma proteins 
referred to as acute-phase proteins (APP) [1-3]. IL-6 is 
also involved in the regulation of N-glycosylation of 
APP in hepatocytes [4]. IL-6 exerts its action via a cell 
surface receptor complex consisting of two components, 
an 80 kDa glycoprotein (gpg0) capable of IL-6 binding, 
and a 130 kDa glycoprotein (gpl30) which does not 
bind IL-6, but is involved in initiation of signal 
transduction [5,6]. The cDNAs of both components 
have been cloned [5,7]. It turned out that the eDNA- 
sequence for gpg0 in hepatocytes is identical to the one 
found in other cell types [8]. Studies on the mechanism 
regulating pg0 and gpl30 expression in hepatocytes 
have demonstrated that gp80 mRNA and its functional 
protein is upregulated by glucocortieoids, but not by 
IL-6 [9]. However, gpl30 mRNA was shown to be 
slightly increased by IL-6 and to a greater extend by the 
combination of IL-6 and glucoeorticoids [10]. IL-6 trig- 
Abbreviations: APP, aeute-pha~e proteins; Con A, coneanavalin A;
CAIE, crossed alTinity-immunoelectruphore~iu; G~cNAc, N-aeetyl- 
glueosamine; GnT, GleNAc-transferase; IL-6, interleukin.6; 1FN, in- 
terferon; LIF, leukemia inhibitory factor; Pl~ a t-protease inhibitor; rh, 
recombinant human; shlL-6-R, soluble human interleukin.6-receptor; 
TGF, transforming growth factor; TNF, tumor necrosi~ factor. 
Correspondence address: S. Rose-John, institut for Bioehemie der 
RWTH Aachen, Pauwelsstrafle 30, 5100 Aachen, Germany. Fax: (49) 
(241) 87 5992. 
gers the association of gpg0 and gpl30 leading to a 
functional 1L-6-receptor complex [6]. 
In hepatocytes IL-6 and gpgO are internalized after 
their interaction resulting in the down-regulation f sur- 
face gp80 [11]. It is presently not known whether gp130 
is intenlalized together with IL-6 and gp80. A gpg0 
mutant lacking cytoplasmic and transmembrane parts 
could functionally substitute for gpg0 [6,7]. Moreover, 
analogous fragments of the gpgO soluble human IL-6- 
receptor (shlL-6-R) were found in human urine [12]. 
APP secreted by the liver carry N-linked complex- 
type giycans, which may be formed as bi-, tri- or tetra- 
antennary structures [13]. Stimulation of hepatocytes 
may either increase or decrease the relative amounts of 
bi- versus multi-branched glycans on the APP polypep- 
tide backbone [14,15]. These changes may be assessed 
using crossed affinity-immunoelectrophoresis (CAIE) 
with the lectin Cola A as a ligand [16]. Con A immuno- 
electrophoresis eparates glycoforms of plasma proteins 
bearing various amounts of bi-antennary N-glycans 
[17]. Forms possessing tri- and/or tetra-antennary N-
glycans do not react with the leetin in CAIE, forms 
having one bi-antennary unit react weakly, forms hav- 
ing two bi-antennary structures react strongly. By as- 
sessing relative amounts of a particular Con A-gly- 
coform of the APP studied it is possible to evaluate 
either relative increases or decreases of bi-antennary 
compared to tri- and/or tetra-antennary N-glyeans. 
The present studies were undertaken to elucidate the 
role played by the shlL-6-g in the regulation of  N- 
glycosylation of APP by IL-6. The studies were carried 
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out usin~ the human hepatoma cell line HepG2 as target 
cell and PI as a typical hepatic APP. HepG2 cells were 
stably transfected with IL-6-cDNA (HepG2-1L-6) and 
used as a model for a 'chronically inflamed liver'. In 
these ceils gp80 is constitutively down-regulated and the 
induction of APP is solely dependent on the addition of 
shlL-6-R. 
2. MATERIALS AND METHODS 
2.1. Reagents 
Restriction en~mes, poiynucicotide kinasc, c~tif intestinal pho.~. 
phatase, T4-DNA ligase were from Boehringer Mannheim (Ger- 
man~,), [r.--~'P]dCTP { 110 TBq/mmol) and [rt -~SS]dATP (44 TBq/mmol) 
were from Amersham International (United Kingdom). Geniticin 
(G418-sulfate) and DM EM were from Gibco (E~genstcin, Germany), 
RhlL.6 was prepared as described in [18]. The specific activity was 
1.5×106 B.cell stimulatory factor 2 units/rag protein [19], Platelet- 
deriv~ purified TGFfll was from R&D Systems Inc. (Mineapolis, 
MN. USA). Rh LIF was a generous gift of Dr. H. Baumann (Buffalo, 
NY, USA) [20], Rh INF? wa~ from Bioferon (Laupheim, Germany), 
Con A type I'V was from Sigma Chem. Co. (St. Louis, Me, USA), 
Polyclonal antiserum against human PI was from Dakopatts (Ham. 
burg, Germany). Human IL.6-cDNA and gpg0-cDNA were isolated 
as described [8,21]. Human PI-cDNA was supplied by Drs. G, Cili. 
berto and R. Cortese (IRBM, Rome, Italy). 
2,2. Cell cultures 
HepG2 cells (ATCC. Rockville, MD. USA) were cultured in 
DMEM/DMEM.FI2 medium. NIH/3T3 cells (ATCC) were grown ia 
DMEM. Culture medium was supplemented with 10% fetal calf 
serum, streptomycin (100 me/l)and penicillin (61 m'Igl), 
2.3. Stable trausfection of cells 
Transfections were carried out as described in [22]. NIH/3T3 cells 
were stably transfected with the expression vector pBMGNeo [23] 
carrying the extracellular domain of the human gpg0-cDNA fused to 
a translational stop codon (H. Sehooltink et al., in preparation) under 
the transcriptional control or the mouse metallothloneln I promoter. 
HepG2 cells were stably transfected with an IL-6-eDNA in the same 
expression vector. 
2.4. General?on of soluble human IL.6.R 
ShlL-6-R was obtained from the conditioned medium of N1H/3T3 
cells transfected with the gpg0-cDNA lacking the sequences coding for 
the transmembrane and cytoplasmic domains. Specific activity of 
shlL-6-R was estimated ina cell.free IL-6 binding assay. One unit was 
defined as the capacity of shlL-6-R to bind 100 n8 of ~'-Sl-rhlL-6 (H. 
Schooltink et el., in preparation). Medium from untransfected NIH/ 
3T3 cells was used as a control. 
2.5. RNA.preparation and Northern blot analysis 
HepG2 and HepG2-IL-6 cells were cultured in the presence of 
cytokines and/or shlL-6-R for 21 h. Subsequently, total RNA was 
prepared [24] and subj~t~.xl to Northern blot anal~sls. A 1.35 kb P~'tl 
fragment of human PI..eDNA was labelled by random priming 1"25] 
and used as a hybridization probe. 
2.6. Determination of the productton and N-glycosylation pattern of Pl 
secreted by HepG2 and HepG2.IL.6 cells 
HepG2 and HepG2-IL-6 cells were incubated with cytokines and 
shlL-6-R l'or 48 h with replacement of medium after 24 h, Analyses 
were carried out in the media collected over the final 24 h. PI secreted 
by hepatoma cells and accumulated in the culture medium was meas- 
ured by an eleetro-immunoassay [26]; accumulation f APP secreted 
by human hepatoma cells into tl~e culture mcdiur,: paralleled the rate 
of synthesis of [~SS]methionine-labelled APP [27], The N-glycosylation 
pattern of Pl was studied by CAIE with Con A [50gM] as a ligand 
117,28], Three glyeoforms were observed (Fig, 2): variant 0=non-reac- 
tive with Con A, composed of three tri-antennary glyeans; variant 
1 =weakly reactive with Con A, composed of I hi- and 2 tri-antennary 
glycans; variant 2=reactive with Con A, composed of 2 hi- and l 
tri-antennary gl cans. The area under the precipitates was determined 
by planimetry and relative amounts of Pl-81ycoforms were expressed 
as percentages of total. In order to express the degree of relative 
changes of N-81ycans composition the Pl-Con A reactivity coeffieient 
(RC) was calculated according to the formula: (sum of Con A reactive 
variants) / (Con A non-reaetiv= ariants). An increase ofth¢ RC value 
reflects increased relative amounts of hi- versus multi-branelled N- 
2.7. IL-6 assay 
IL-6 was measured using the IL-f-dependent murine plasmacytoma 
cell line Bg, generously supplied by Dr. L. Aarden (Amsterdam, The 
Netherlands) [29], 
2.8. ShIL.6.R assay 
NIH/3T3 conditioned media (i00 el) were incubated in a total 
volume of 500 gl of PBS containing 0,01% Twcen 20 with [J a~l]rhIL-6 
for 3 h at 4°C followed by incubation with a monospeeific polyclonal 
antiserum against shlL-6.R (T, Stoyan et al., in preparation), The 
immunocomplexes were precipitated usin 8 protein(A)-Sepharose and 
counted in a 7-counter, 
3. RESULTS 
In HepG2 cells IL-6 moderately increased in a dose- 
dependent manner PI synthesis at mRNA (Fig. I) and 
protein (Table I) levels. Addition of shlL-6-R to the 
incubation medium enhanced the effect of IL-6. IL-6 
decreased Con A reactivity of Pl secreted by HepG2 
cells with a maximum at the dose of 100 U/ml (Fig. 2, 
Table I). ShIL-6-R augmented the IL-6 effect, especially 
at high doses of IL-6 (Table l). Increasing concentra- 
tions of shlL-6-R added to a constant amount of IL-6 
amplified its effect in decreasing PI-Con A reactivity in 
a dose-dependent manner with a maximum at a dose of 
5 U/ml (data not shown). 
HcpG2-IL-6 cells constitutively synthesized and se- 
creted rhIL-6 in amounts of 2 #g/10 ° cells/24 h. These 
cells showed similar levels of PI mRNA and secreted 
comparable quantities of PI as non-transfected HepG2 
cells in the absence of IL-6. Con A reactivity of PI was 
also comparable to that of PI from intact non-stimu- 
lated HepG2 cells (Fig. 2). Treatment of HcpG2-IL-6 
cells with ZnCh or addition of exogenous IL-6 did not 
change PI-mRNA or PI-Con A reactivity (data not 
shown). Exposure of these cells to LIF, INF 7 or TFGfl 
affected PI-Con A reactivity (Fig. 2, Table I) while it 
had only a marginal effect on PI mRNA levels (Fig. 1). 
Addition of shIL-6-R to HepG2-IL-6 cells resulted in 
a dose- and time-dependent induction of PI mRNA and 
protein (Fig. 1). ShIL-6-R significantly decreased Con 
A reactivity of PI secreted by these cells in a dose- 
dependent manner with a maximum at 5 U/ml (Fig. 2, 
Table I). 
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Fis. 1, Northern blot analysi~ of gl-protease inhibitor: (A) Induction of PI-mRNA by IL-6 and combinations of IL-6 and shlL-6-R in HepG2 cells; 
(B) effect of shlL-6-R, LIF, TGFfl, IFN7 and dexamelhasone on PI-mRNA expression in HeI~2 cells stably transfected with IL-fi-eD~IA 
(HepG2-1L-6 cells). Time- (C) and dose- (D) dependent induction of PI-mRNA by shlL-6.R in HepG2-IL.6 cells. 
4. DISCUSSION 
There are three major findings of this study: (i) shlL- 
6-R enhances the IL-6 effect on the N-glycosylation of 
PI secreted by HepG2 cells; (ii) prolonged exposure of 
HepG2 cells to IL-6 leads to their homologous desensi- 
tization; (rid shlL-6-R reconstitutes the responsiveness 
of IL-6-desensitized HepG2 cells as measured by 
changes in PI N-glycosylation. 
Soluble cytokine receptors have been identified for a 
number of cytokin.-s (reviewed in [30]). Their function, 
however, still remains unknown. They are generally be- 
lieved to compete for the ligand with their membrane 
counterparts which finally leads to a decrease in the 
Table 1 
Effect or shlL-6.R on synthesis and Con A.reactivity or pl secreted by I-lepG2 and HeI~I2-IL-6 cells 
Pl-synthesis" Con A-reactivity (RC b) 
shlL-6-R (5 U/ml) - ÷ - d- 
HepO2 
HepG2.1L-6 
Control 100 14)0 3.5 3.5 
IL.6 l (U/ml) 105 110 2.4 2.2 
IL-6 10 (U/ml) 120 140 1.5 1.0 
IL-6 100 (U/ml) 155 200 1.3 0.6 
IL-6 1000 (U/ml) 150 200 1.6 1.0 
Control 100 4.0 
shlL-6-R 1,0 (U/ml) 140 1,2 
2.5 (U/ml) 180 0.75 
5.0 (U/ml) 220 0.7 
7.5 (U/ml) 200 1.0 
10 (U/ml) 180 1.2 
LIF 10 (U/ml) 130 1.2 
TGFfl 2 (ng/ml) 120 5.6 
INF,, 100 (n~/ml) 90 2.7 
Analysis was carried out by means of cl~troimmunoas~ay. R~ults arc expr~s,~d aspereentage~ of the control and represent mean values of four 
exl~riments. 
aAnalysis was carried out by means of crossed affinity-immunoel~trophoresis with Con A as a ligand. RC -- reactivity coefficient of PI-Con A 
calculated as describ~ in M~terlals and Methods. 
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Fig. 2. Con A affinity electrophoresis of PI secreted by HepG2 (upper part) and HepG2-1L-6 cells (lower part) upon incubation with IL-6 (100 
U/ml), shlL.6-R (5 U/ml, 7.5 U/ml), LIF (10 U/ml), IFNy (109 U/ml)and TGF/~ (4 ng/ml). Incubation of HepG2 cells with IL.6 and shlL-6.R 
was performed at concentrations of 100 U/ml and 5 U/ml or IL-6 and shlL-6-R, respectively. PI variant 0 - non reactive with Con A; variant 1 
- xveakly reactive; varia,~t 2 - reactive with Con A. 
biological activity of the cytokine. Our findings indicate 
that soluble IL-6-Rs display a unique activity resulting 
in the enhancement of IL-6 effects on hepatocytes. This 
is supported by the loss of responsiveness of HepG2 
cells following continuous exposure to IL-6. The possi- 
ble mechanism involved is probably related to the 
down-regulation of the gpg0-1L-6 binding protein [11]. 
Interestingly, responsiveness of IL-6-desensitized cells 
could be reconstituted by shIL-6-R which functionally 
substitutes for membrane-bound gpg0. 
During various inflammatory processes changes in 
the N-glycosylation profiles of APPs in patient sera 
were observed [31]. In 'acute inflammation' increases 
(type I), in 'chronic inflammatory states' decreases (type 
I1) in relative amounts of hi- versus multi-branched N-
glycans were found [31]. In some inflammatory disor- 
ders such as systemic lupus erythematodes (SLE) [32] or 
AIDS (A. Mackiewicz et al., in preparation) no altera- 
tions in N-glyeosylation were seen. However, intercur- 
rent infection in the course of SLE leads to type I 
changes [32]. Alterations in APP N-glycosylation seem 
to be controlled by cytokines affecting hepatocytes 
[17,28]. IL-6 is a major inducer of both types of altera- 
tions in N-glycosylation [4]. Other cytokines such as 
TGFfl, LIF, INF,', TNFcc or IL-I interact with IL-6 
which finally leads to type ! or type II changes [17,28]. 
Here we report that shlL-6-R may be an important 
component of the regulatory network governing N-gly- 
cosylation of APP. 
In view of our findings and the recent report on high 
IL-6 levels in SLE patient sera [32] no alterations in 
N-glycosylation of APP could be associated with down- 
regulation of gp80 on the hepatocytes and subsequent 
desensitization to IL-6 in these patients. Furthermore, 
type I alterations seen in SLE patients with intercurrent 
infection [33] might be attributed to the effect of shlL- 
6-R. 
Post-translational modification of oligosaccharide 
side chains of glycoproteins i a multi-step enzymatic 
process. Highly specific glyeosidases and glycosyltrans- 
ferases equentially process an oligosaccharide precur- 
sor to yield various types of N-linked glycans [34]. The 
branches that occur on complex-type oligosaccharides 
are initiated by the incorporation of a N-acetyl-glu- 
eosamine (GIcNAc) residue. This reaction is catalyzed 
by GlcNAc-transferases (GnT). GriT 1II, GnT IV anti 
GnT V catalyze the formation of bi-, tri- av~d tetra- 
antennary structures, respectively. Control of the level 
of relative activity of different GnTs is one of the regu- 
lating mechanisms of branching during the synthesis of 
complex-type N-linked oligosaecharides. Recently, IL-6 
has been demonstrated to increase GriT IV and GnT V 
activity and decrease GriT III activity accompanied by 
an increase of tri- and tetra-antennary glycans on 
glycoproteins [35]. It should be noted that reduced Gri t  
II1 activity might also contribute to the formation of 
multi-branched structures, since Gr i t  III and GnT V 
compete for the same substrate [36]. Accordingly, the 
IL-6 effect on changes in the N- glycosylation profile of 
PI is most probably due to the regulation of gene ex- 
pression of GnTs. 
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